Abstract:
The present invention relates to a composition connprising polysaccharides and whey protein micelles for use in the treatment or prevention of a disorder linked to an increase in plasma postprandial insulin in a subject. The invention relates also to the non-therapeutic use of a composition comprising polysaccharides and whey protein micelles to decrease plasma postprandial insulin concentration. A further aspect of the invention is a process for forming polysaccharide-whey protein micelle complexes.
Abstract:
La présente invention a pour objet une composition pharmaceutique comprenant au moins un agent humectant, un agent gélifiant et un agent filmogène pour son utilisation dans le traitement de l'hyposialie ou de l'asialie.
Abstract:
One aspect of the invention provides dietary fiber compositions comprising effective amounts of glucomannan, xanthan gum, and alginate to produce a desired viscosity. The invention also provides food products comprising an effective amount of a dietary fiber composition. In other aspects, the invention provides methods for preparing a dietary fiber composition or a food product comprising a dietary fiber composition, and methods for promoting satiety, promoting weight loss, lowering blood glucose levels, or lowering blood cholesterol levels in a mammal.
Abstract:
The invention concerns the use of a compound or a number of compounds from the group of the carbohydrates or carbohydrate derivatives as anti-adhesive active principles directed against micro-organisms, parasites and protozoa.
Abstract:
The present invention provides a pharmaceutical composition comprising a probiotic and a prebiotic for alleviating symptoms associated with infections such as neonatal sepsis and pneumonia in neonates and infants. More particularly, the pharmaceutical composition comprises at least one Lactillobacillus specie(s) as a probiotic and at least one oligosaccharide or at least one polysaccharide as a pre-biotic. The present inventon further provides a method of treatment of neonatal sepsisand pneumonia comprising administering an effective amount of the pharmaceutical composition to neonates and infants in need thereof.
Abstract:
In a general embodiment, a method for increasing efficacy of a swallow response is provided. The method includes providing a thickened composition having a xanthan gum thickening component, and orally administering the composition to an individual having, or at risk of having, a swallowing impairment. In an embodiment, the efficacy of the swallow response is increased by reducing an amount of pharyngeal residue in the individual's piriform sinuses, valleculae, and/or pharyngeal wall during or after the individual swallows the composition.
Abstract:
Embodiments of the present description provide a blend for use in a personal care product having a modified xanthan gum and a galactomannan, wherein the modified xanthan gum is a non-pyruvylated xanthan gum, and the modified xanthan gum and the galactomannan are present in the blend in a ratio from about 1 :99 to about 99: 1 by weight. Also provided in embodiments of the present description are personal care products having blends of modified xanthan gums and galactomannans, methods for product formulation, and use thereof.